| Market Cap | 5.91M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -6.75M | Forward P/E | -0.22 | EPS next Y | - | 50D Avg Chg | -40.00% |
| Sales | 1.11M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -90.00% |
| Dividend | N/A | Price/Book | 0.30 | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | - | Quick Ratio | 6.28 | Shares Outstanding | 6.18M | 52W Low Chg | 24.00% |
| Insider Own | 0.34% | ROA | -89.18% | Shares Float | 5.98M | Beta | 2.50 |
| Inst Own | 10.00% | ROE | -183.60% | Shares Shorted/Prior | 81.43K/67.86K | Price | 0.05 |
| Gross Margin | 27.85% | Profit Margin | - | Avg. Volume | 12,481,108 | Target Price | - |
| Oper. Margin | -861.43% | Earnings Date | - | Volume | 35,973,514 | Change | 13.26% |
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
